Table 5.

Preference weights for vaccine eagerness, 7–30 June 2023, Guadeloupe

	All respondents (N = 389)			Serial non-demanders (N = 133)			All respondents reporting a child not vaccinated against HPV and reporting no intention to vaccinate (N = 111)
	Coeff	[95% confidence interval]		Coeff	[95% confidence interval]		Coeff	[95% confidence interval]
Disease
Genital and oral warts	Ref			Ref			Ref
Cancer prevention	0.48	0.06	0.90	0.06	−0.08	0.21	0.33	−0.39	1.05
Prevention of pregnancy complications	−0.15	−0.55	0.24	0.09	−0.05	0.23	−0.13	−0.80	0.55
Sexual discomfort	−0.12	−0.55	0.32	−0.03	−0.19	0.13	−0.29	−1.04	0.47
Vaccine safety
No side effects	Ref			Ref			Ref
Long term observation	0.13	−0.33	0.58	−0.01	−0.18	0.15	−0.23	−1.01	0.55
WHO: vaccine effective and safe	−0.49	−0.91	−0.06	−0.14	−0.29	0.01	−0.98	−1.71	−0.25
Favorable risk–benefit balance	−0.37	−0.79	0.06	−0.14	−0.29	0.01	−0.19	−0.91	0.53
Recommendation sources
Ministry of Health and regional health authority	Ref			Ref			Ref
School health and maternal and Child welfare services	0.00	−0.39	0.38	0.02	−0.12	0.15	−0.44	−1.10	0.22
General practitioner	−0.07	−0.43	0.30	0.06	−0.07	0.19	−0.47	−1.09	0.16
Social conformity
Low vaccination coverage in adolescents (15%)	Ref			Ref			Ref
High vaccination coverage in adolescents (70%)	0.80	0.41	1.19	0.04	−0.10	0.18	0.45	−0.22	1.12
High vaccination coverage in adolescents (> 70%) in Puerto Rico and Canada	0.76	0.38	1.15	−0.03	−0.17	0.11	0.57	−0.09	1.23
Optimal age
Vaccine effective at all ages	Ref			Ref			Ref
Vaccine more effective before 14 years: optimal antibody production	0.71	0.33	1.09	0.03	−0.11	0.17	1.23	0.57	1.89
Vaccine more effective before sexual debut	0.37	0.01	0.73	−0.06	−0.19	0.07	0.17	−0.46	0.79